Andrew Saxon, MD

Recent Publications

Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
(2021 Aug 28)
Drug Alcohol Depend 228(): 108996
Zhu Y, Mooney LJ, Yoo C, Evans EA, Kelleghan A, Saxon AJ, Curtis ME, Hser YI

Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
(2021 Sep 6)
Addict Sci Clin Pract 16(1): 55
Hawkins EJ, Danner AN, Malte CA, Blanchard BE, Williams EC, Hagedorn HJ, Gordon AJ, Drexler K, Burden JL, Knoeppel J, Lott A, Sayre GG, Midboe AM, Saxon AJ

Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III).
(2021 Aug 19)
Am J Psychiatry
Browne KC, Stohl M, Bohnert KM, Saxon AJ, Fink DS, Olfson M, Cerda M, Sherman S, Gradus JL, Martins SS, Hasin DS

Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.
(2021 Oct 1)
Drug Alcohol Depend 227(): 108917
Tsui JI, Leroux BG, Radick AC, Schramm ZA, Blalock K, Labelle C, Heerema M, Klein JW, Merrill JO, Saxon AJ, Samet JH, Kim TW

High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder.
(2021 Jul 1)
JAMA Netw Open 4(7): e2117128
Herring AA, Vosooghi AA, Luftig J, Anderson ES, Zhao X, Dziura J, Hawk KF, McCormack RP, Saxon A, D'Onofrio G

Show complete publication list »
Edit Profile